EpiStem Holdings plc
05 March 2008
Epistem strengthens management team with the appointment of Lydia Meyer-Turkson
as Director of Biomarker Division.
Epistem is pleased to announce the appointment of Lydia Meyer-Turkson as
Director of its emerging Biomarker Division. Lydia will lead the continued
expansion of the Division managing strategic collaborations with Pharmaceutical
and Biotechnology companies using Epistem's plucked hair biomarker technology.
Lydia brings more than 14 years Business Development experience of Contract
Research in drug development. Prior to joining Epistem, Lydia had been VP
Business Development at Evotec, where she identified, structured, negotiated and
closed drug discovery collaborations in Europe key to the company's business
strategies. Lydia has previously held senior commercial roles with US contract
research companies including Quintiles and Covance. She holds a BSc and MPhil in
Chemistry from University College Cardiff and an MBA from Manchester Business
School.
On the commencement of her employment with Epistem, Lydia was awarded share
options as detailed below. The share options will vest according to the sales
performance of the Biomarker Division over the period to 30th June 2011.
The share options have an exercise price of 153 pence, being the closing share
price on 4th March 2008.
Following this award, Lydia will hold the following numbers of share options:
Senior Executive Share option New share options Total share option Share options held as
holding prior to granted holding after % of issued capital
award award
L Meyer-Turkson 0 71,918 71,918 1%
For further information, please contact:
Matthew Walls, CEO/John Rylands, Financial Director
Epistem Holdings Plc
Tel: +44 (0)161 606 7258
Thilo Hoffmann/Gareth Price
Landsbanki Securities (UK) Limited
Tel: +44 (0)207 426 9000
Mike Wort / Anna Dunphy
De Facto Communications Limited
Tel: +44 (0)207 861 3838
This information is provided by RNS
The company news service from the London Stock Exchange